HSBC Issues Pessimistic Forecast for Repligen (NASDAQ:RGEN) Stock Price
HSBC cut its price target for Repligen (RGEN) from $170 to $150 while keeping a “buy” rating, implying 23.1% upside from the prior close, according to the report cited by Benzinga. Other firms adjusted targets as well. Repligen reported Q1 EPS of $0.48 on revenue of $194.26M and set FY2026 guidance of 1.97–2.05 EPS.
Broker target-price reset increases near-term valuation pressure and can influence momentum/positioning in RGEN.
HSBC cut its Repligen target price from $170 to $150 while keeping a “buy” rating, signaling a more cautious valuation view.
Mild-to-moderate downside bias versus prior expectations; likely supports volatility around analyst/consensus updates.
Background
The piece summarizes HSBC’s revised target and broader sell-side stance, then provides recent trading/financial context (midday price, prior earnings beat, and FY2026 EPS guidance).
Why it matters
A target-price reduction can shift short-term positioning and expectations even without a rating change; however, the company’s recent earnings beat and guidance may counterbalance.
Market relevance
Valuation expectations for RGEN are being marked down by a major broker, with potential to affect near-term sentiment and trading ranges.
Market effects
Bioprocessing/biotech equipment names may see read-across from valuation resets, especially for high-multiple stocks.
Primarily US biotech sentiment; limited direct regional spillover beyond analyst-driven flows.
Low—this is a single-company broker note rather than a global supply/demand or regulatory shift.
Alternative perspectives
Because HSBC kept a “buy,” the cut may reflect valuation normalization rather than deteriorating fundamentals, limiting downside follow-through.
The article also notes recent earnings beat and FY2026 EPS guidance; traders may weigh that against the target cut when re-pricing risk.
Key entities
- companyRepligen
Biotechnology company whose HSBC target price was reduced and whose recent earnings/guidance are referenced.
- brokerHSBC
Issued the updated (lower) price target for RGEN while maintaining a buy rating.
